top of page

Ixiaro is the only vaccine approved in the U.S. for Japanese encephalitis

Japanese encephalitis

What is IXIARO®?

IXIARO® is a vaccine used for prevention of Japanese encephalitis for people 2 months of age and older.[1]

Ixiaro is shown to be highly effective in numerous trials

We reviewed the safety of the JE vaccine in another post. See the effectiveness information below. Note that even in breakthrough cases where a person does become ill with JE after having been vaccinated, we would expect the illness from JE to be less severe.

Ixiaro vaccine schedule

For adults aged 18-65, the vaccine is given in 2 doses, 7 days apart (accelerated schedule) or 28 days apart (standard schedule), and vaccination should be completed 7 days before departure. Accelerated schedule is not recommended for children and adults over 65 years old. A booster dose (third dose) may be given at least 11 months after completion of the primary immunization series if ongoing exposure or re-exposure to JE virus is expected.[1]

Possible side effects of Ixiaro

Common adverse reactions include fever, irritability, diarrhea, and injection site redness in those up to 1 year of age; fever in children up to age 12, and pain and tenderness in adolescents. In adults the most common side effects are headache, myalgia, and injection site pain and tenderness.[1]

Manufacturer of Ixiaro

Valneva is a specialty vaccine company focused on the development, manufacturing and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to commercialize three vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease and the chikungunya virus.


  1. IXIARO [prescribing information]. Vienna, Austria; Valneva Austria GmbH; 2018.


bottom of page